# Two different versions of cognitive behaviour therapy for body dysmorphic disorder

Submission date	Recruitment status  No longer recruiting	Prospectively registered		
31/03/2009		☐ Protocol		
Registration date	Overall study status	Statistical analysis plan		
20/10/2009	Completed	[X] Results		
Last Edited	Condition category	Individual participant data		
22/03/2016	Mental and Behavioural Disorders			

# Plain English summary of protocol

Not provided at time of registration

# Contact information

# Type(s)

Scientific

#### Contact name

Dr David Veale

#### Contact details

Centre for Anxiety Disorders and Trauma 99 Denmark Hill London United Kingdom SE5 8AZ +44 (0)20 3228 3461 david.veale@iop.kcl.ac.uk

# Additional identifiers

ClinicalTrials.gov (NCT)

NCT00871143

Protocol serial number

N/A

# Study information

Scientific Title

A randomised controlled trial of two different versions of cognitive behaviour therapy for body dysmorphic disorder

## **Study objectives**

The hypotheses to be tested are that:

- 1. Specific cognitive behavioural therapy (CBT) for body dysmorphic disorder (BDD) will be more effective than non-specific CBT at 12 weeks
- 2. Treatment effects from specific CBT will be maintained at 1 month, 3 months and 1 year follow-up

## Ethics approval required

Old ethics approval format

# Ethics approval(s)

The Joint South London and Maudsley and the Institute of Psychiatry Research Ethics Committee (REC), 23/03/2009, ref: 09/H0807/9

# Study design

Single-centre single-blinded parallel-group randomised controlled trial

# Primary study design

Interventional

# Study type(s)

Treatment

# Health condition(s) or problem(s) studied

Body dysmorphic disorder

#### **Interventions**

CBT specific for BDD:

A pilot study 12 years ago has demonstrated a significant benefit of CBT over a waiting list. The mean reduction was about 50% on the primary outcome measure (YBOCS for BDD). This consisted of a reduction of 12 points and a standard deviation of 7 on the YBOCS for BDD and the treatment is now thought to be better than in 1996.

## CBT not specific for BDD:

Stress management and cognitive restructuring, which has been shown to be a credible alternative psychological treatment to CBT in health anxiety. However, in two pilot cases of BDD, the benefits were minimal with a reduction of between zero and 10% on the YBOCS for BDD. At the most this equates to a maximum of 3 points reduction.

The treatments are provided over 12 weeks (twice a week for the first 4 weeks and once a week for 8 weeks). For CBT specific to BDD there will be three follow-up sessions at 1 and 3 months and at 1 year, making a maximum total of 19 sessions.

#### Intervention Type

Other

#### **Phase**

Not Applicable

## Primary outcome(s)

Yale Brown Obsessive Compulsive Scale (modified for BDD) (BDD-YBOCS), which will be done by a blind assessor at 12 weeks.

## Key secondary outcome(s))

Two observer-rated scales:

- 1. Brown Assessment of Beliefs to measure the strength of conviction in beliefs about being ugly
- 2. Montgomery Asberg Depression rating scale

Five brief self-rated scales:

- 1. The Body Image Quality Of Life (BIQL) inventory, which is a disorder-specific quality of life measure and used in BDD
- 2. Depression (nine-item Patient Health Questionnaire [PHQ9])
- 3. Anxiety (Generalised Anxiety Disorder Assessment [GAD7])
- 4. Appearance Anxiety Inventory (AAI)
- 5. EQ5-D, a measure of health-related quality of life

Patients will be reassessed on all measures at 6 and 12 weeks. Patients in the CBT specific for BDD group will be assessed at 1 month, 3 months and 1 year following treatment. In addition, the PHQ9, GAD7 and AAI are measured weekly for case tracking during treatment. The primary end-point is at 12 weeks. Patient preference as to treatment group and their expectations and beliefs about treatment (pre- and post-) will also be recorded.

#### Completion date

01/04/2011

# Eligibility

#### Key inclusion criteria

- 1. BDD is the main psychological problem. We will use Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria as BDD does not exist as a separate diagnosis in the International Classification of Disease, version 10 (ICD-10). They may have an additional diagnosis of delusional disorder when it refers to beliefs about being ugly or defective.
- 2. They must have a total of 24 or more on the twelve-item Yale-Brown Obsessive Compulsive Scale (YBOCS) modified for BDD
- 3. They may be of either gender but must be 17 years or above
- 4. They are willing to travel to the treatment centre for weekly sessions
- 5. They are willing to complete regular questionnaires and be audiotaped for supervision and for listening to enhance their learning
- 6. They may be taking psychotropic medication so long as it is stabilised and there are no plans to increase the dose

# Participant type(s)

Patient

# Healthy volunteers allowed

No

# Age group

Adult

#### Sex

All

## Key exclusion criteria

- 1. They have a current or past diagnosis of schizophrenia, bipolar affective disorder
- 2. They have current suicidal intent or severe self-neglect that requires hospitalisation
- 3. They have a current alcohol or substance dependence or anorexia nervosa or borderline personality disorder that requires treatment in its own right
- 4. They are currently receiving any other form of psychotherapy
- 5. They have received CBT for BDD in the past 6 months, which is judged as competently delivered and did not respond
- 6. They cannot speak sufficient English for CBT (assistance will be provided for those who speak English but are unable to read questionnaires)

#### Date of first enrolment

01/04/2009

#### Date of final enrolment

01/04/2011

# Locations

#### Countries of recruitment

United Kingdom

England

Study participating centre Centre for Anxiety Disorders and Trauma

London United Kingdom SE5 8AZ

# Sponsor information

## Organisation

Institute of Psychiatry, Kings College London (UK)

#### **ROR**

https://ror.org/0220mzb33

# Funder(s)

# Funder type

University/education

#### Funder Name

Institute of Psychiatry, Kings College London (UK) - Biomedical Research Centre for Mental Health (ref: PAXKAYR)

# **Results and Publications**

Individual participant data (IPD) sharing plan

# IPD sharing plan summary

Not provided at time of registration

# **Study outputs**

Output type	Details	Date created Date adde	d Peer reviewed?	Patient-facing?
Results article	results	01/02/2014	Yes	No
Basic results			No	No
Participant information sheet	Participant information sheet	11/11/2025 11/11/202	5 No	Yes